Best response in individual patients with HMA-naïve CMML in part 2B
| Patient no. . | Days from diagnosis to treatment . | Best response and allo-HCT . | Duration of response∗, d . |
|---|---|---|---|
| 1 | 47 | CB (KRAS gene mutation cleared, monocytes decreased to normal, platelet count increased to normal, and MPN-SAF TSS reduced from 28 to 0) | 469 (ongoing) |
| 2 | 1201 | CR | 293 (ongoing) |
| 3 | 45 | CR and allo-HCT | 288 |
| 4 | 34 | CB (KRAS, and PTPN11 gene mutation cleared, blasts reduced, monocytes reduced to normal, Hgb increased to normal, transfusion independent, and MPN-SAF TSS reduced from 21 to 1) | 140 (ongoing) |
| 5 | 31 | CR | 112 (ongoing) |
| 6 | 243 | CR and allo-HCT | 78 |
| 7 | 110 | CB (reduction of blasts and monocytosis) | 63 |
| 8 | 67 | NR | |
| 9 | 119 | CB (monocytes reduced to normal and MPN-SAF TSS reduced from 31 to 7) | 130 (ongoing) |
| 10 | 30 | NR | |
| 11 | 51 | MR (KRAS gene mutation cleared and reduction of blasts and monocytosis) and allo-HCT | 25 |
| 12 | 233 | NR | (ongoing) |
| 13 | 126 | CB (reduction of blast and monocytosis, transfusion-independent, Hgb increased to normal, and posttreatment KRAS mutation data not available) and allo-HCT | 91 |
| 14 | 126 | CR and allo-HCT | 56 |
| 15 | 188 | NR (monocytes reduced to normal) and allo-HCT | |
| 16 | 155 | MR (monocytes reduced to normal and blasts reduced) and allo-HCT | 68 |
| 17 | 89 | NR | |
| 18 | 14 | NR |
| Patient no. . | Days from diagnosis to treatment . | Best response and allo-HCT . | Duration of response∗, d . |
|---|---|---|---|
| 1 | 47 | CB (KRAS gene mutation cleared, monocytes decreased to normal, platelet count increased to normal, and MPN-SAF TSS reduced from 28 to 0) | 469 (ongoing) |
| 2 | 1201 | CR | 293 (ongoing) |
| 3 | 45 | CR and allo-HCT | 288 |
| 4 | 34 | CB (KRAS, and PTPN11 gene mutation cleared, blasts reduced, monocytes reduced to normal, Hgb increased to normal, transfusion independent, and MPN-SAF TSS reduced from 21 to 1) | 140 (ongoing) |
| 5 | 31 | CR | 112 (ongoing) |
| 6 | 243 | CR and allo-HCT | 78 |
| 7 | 110 | CB (reduction of blasts and monocytosis) | 63 |
| 8 | 67 | NR | |
| 9 | 119 | CB (monocytes reduced to normal and MPN-SAF TSS reduced from 31 to 7) | 130 (ongoing) |
| 10 | 30 | NR | |
| 11 | 51 | MR (KRAS gene mutation cleared and reduction of blasts and monocytosis) and allo-HCT | 25 |
| 12 | 233 | NR | (ongoing) |
| 13 | 126 | CB (reduction of blast and monocytosis, transfusion-independent, Hgb increased to normal, and posttreatment KRAS mutation data not available) and allo-HCT | 91 |
| 14 | 126 | CR and allo-HCT | 56 |
| 15 | 188 | NR (monocytes reduced to normal) and allo-HCT | |
| 16 | 155 | MR (monocytes reduced to normal and blasts reduced) and allo-HCT | 68 |
| 17 | 89 | NR | |
| 18 | 14 | NR |
Included were 18 patients from the efficacy analysis set.
Hgb, Hemoglobin; NE, not evaluable; NR, no response.
Duration of response was calculated based on the time interval between the first response date and the documented date of either disease progression or allo-HCT or the data cutoff date (for responders with ongoing treatment).